Company intelligence / Profile preview
Genis
Siglufjordur, Icelandgenis.is ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Genis is pioneering the use of therapeutic chitin derivatives for pharmaceutical applications in inflammatory diseases and orthobiologic medical devices. The company has invested approximately $40M USD in R&D over two decades, with a robust IP portfolio. Their lead science focuses on the anti-inflammatory properties of chitooligosaccharides and the regenerative/antibacterial properties of their proprietary ChitoBiomer for bone implants. Clinical results are not yet published or available as of now; programs appear to be preclinical or early-stage.
- Therapeutic areas
- PulmonologyRheumatologyImmunology
- Modalities
- Chitin derivatives (including chitooligosaccharides and ChitoBiomer)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Genis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genis.